Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
about
Mechanisms of action of glucagon-like peptide 1 in the pancreasThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisThe pharmacological landscape and therapeutic potential of serine hydrolasesLixisenatide as add-on therapy to basal insulinInvolvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formationDesign and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitorsIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extractsStereoselective synthesis of novel adamantane derivatives with high potency against rimantadine-resistant influenza A virus strains.Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Analysis of the proteolysis of bioactive peptides using a peptidomics approach.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesInvestigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialSaxagliptin for type 2 diabetesAntimicrobial and hypoglycemic activities of novel N-Mannich bases derived from 5-(1-adamantyl)-4-substituted-1,2,4-triazoline-3-thionesPatient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetesA substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.The metabolic serine hydrolases and their functions in mammalian physiology and disease.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiationInvestigating endogenous peptides and peptidases using peptidomicsChoosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic modelSelective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Management of Type 2 diabetes: the role of incretin mimetics.Unstabilized azomethine ylides for the stereoselective synthesis of substituted piperidines, tropanes, and azabicyclo[3.1.0] systemsDipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated CardiomyopathyPolycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.Exploration of the DPP-4 inhibitors with a focus on saxagliptin.Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.Incretin agents in type 2 diabetes.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
P2860
Q24683764-77FB0BD8-0064-4263-917D-21B501AE7218Q26795473-6B7D746E-D4F1-4F61-B167-2331D7136C58Q26995817-3103F040-EC05-4380-97FA-1F459C3D2FA3Q27007547-48911E3B-D566-4A61-A5DD-7D0F7133D35CQ27649728-A9C3CE36-6FD1-484E-8F06-6F2F99519E7FQ27684616-658E2524-41B4-4BD9-9DDC-F1889D04EA0DQ28483936-BD625EB1-1D4B-489C-A83D-1B947AFDBB1BQ30400276-3497023A-D2D0-4653-8EB2-DA1055B59C04Q31036099-65453622-E935-420B-9D08-FFC0807420D3Q33237060-7505E4B1-E7F1-44F1-B869-FADAFD497D39Q33671491-6EA3175B-6DF3-46EE-B3AD-0FFCD88C2BA5Q34219918-54C9A037-3CD3-45BF-963D-74D642507B66Q34222114-63210115-E8DC-4A36-A281-333DD0247574Q34329204-4BA2B6DE-1F10-41EC-91B5-8054D4EACCDDQ34573849-BF05EA88-7DEA-415C-AD78-2B1E45DFB00FQ34608300-F857C477-55E0-43C5-8520-702C831FCA28Q34610019-345743F1-EB4D-4D8F-B307-C6C1A7A3CFFDQ34620486-4E4DEBBF-124C-49E6-89CA-C8057D4DDF75Q34835155-A2F74E1C-91E9-4221-9C3B-F862D72F04A7Q35115112-9B55E896-B3A7-4DDD-BA1A-90DDAD1270A6Q35131941-59E78235-4B27-4411-B06B-F2DBEA0BAA12Q35333042-C11A23F0-EBAF-4C83-BA4C-E5AC45268951Q35916947-8106B24C-A3FA-4CC5-8EBF-5EB78056138EQ36163374-0018C787-4164-4442-8B32-F641DA29F17DQ36355550-4129DEF3-F922-4DAF-98AB-E628FC5292A1Q36470223-B52FD951-27A8-4E00-9A3A-CF148387A3A7Q36580568-7FCFD451-65E5-4490-800D-C9179963B9D5Q36580608-7CC80CEC-3D5F-40CF-A056-94FE97B107A5Q36613938-4DE28175-B709-4137-88DE-7C924C894012Q36651992-DEE0CAF7-3F62-44B5-BD9D-04680006C0A0Q36735761-3CC87722-3124-4D89-85B2-7871E6A2B0BEQ36892807-E80B5140-F79C-446D-A733-3CF6901DC8F8Q36939647-9B2A1222-D4D2-4157-BAF1-1040D796AB9FQ37358680-6E0EEEEC-CF1B-41E9-9F0C-1026EE0CD517Q37384190-AAF27ED8-BA3E-4A1D-BAD8-0E37763E8F95Q37603371-28CEEA78-3C13-46E2-8D35-FD81B4373F62Q37636165-5A319844-C4B6-4954-AFF2-CCDE0F960D9FQ37682555-77368689-2E5C-4A7D-B82B-1418772DE283Q37772709-538E0E3C-5BFB-47D7-B3E6-0EA6412389A7Q37941683-D33B5B92-12EC-4913-90B5-B9531CBE8D8E
P2860
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@ast
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@en
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@nl
type
label
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@ast
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@en
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@nl
prefLabel
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@ast
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@en
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@nl
P2093
P3181
P356
P1476
Discovery and preclinical prof ...... e treatment of type 2 diabetes
@en
P2093
Aiying Wang
Ashish Khanna
Benoni Abboa-Offei
David A Betebenner
David J Augeri
David R Magnin
Donald M Egan
Effie Tozzo
Gustav E Welzel
James G Robertson
P304
P3181
P356
10.1021/JM050261P
P407
P577
2005-07-28T00:00:00Z